Research Summary: Candida

As featured in Dr. Kenny Mittelstadt's video:
Candida Treatments That Actually Work (And Why Most Don't Last)
Date of Publication: 06/11/2026

Research Context:

This week's topic explores how candida overgrowth isn't simply about the presence of a pathogen. It's about what changed in the gut environment that allowed a normal resident to shift into a problematic form. The studies below help explain why treatment alone often falls short, and what the research reveals about the bacterial terrain that keeps candida in check.

Key Findings from the Research:

Study 1 (PMID 40788152 | Marsaux et al., 2025):

Using a lab model designed to simulate conditions in the human colon, researchers tracked what happened to candida when specific bacterial populations shifted. They found that candida expansion was not tied to an overall drop in bacterial diversity. It was tied specifically to the depletion of bacteria that produce butyrate, a short-chain fatty acid that keeps the gut environment appropriately acidic and limits candida's ability to grow and shift into its more invasive form. The two families most clearly connected to this protective effect were Lachnospiraceae and Bifidobacterium. This is a mechanistic model study, not a human clinical trial, so the findings point to a biological pattern worth investigating rather than a confirmed clinical outcome.

Study 2 (PMID 40788152 | Bays & Savage, 2025):

This review examined the relationship between the gut microbiome and candida colonization resistance, meaning the gut's built-in capacity to keep candida from expanding. The authors describe colonization resistance as an active, ongoing process driven by the microbial community, not a passive state. When that community is disrupted, whether by antibiotics, dietary patterns, or other stressors, the suppressive capacity weakens and candida gets the environmental opening it needs. The review frames this as a host-microbiome balancing act, where the terrain, not the organism alone, determines the outcome.

Study 3 (PMID 35680868 |Alonso-Roman et al., 2022):

This mechanistic study looked at what happens when Lactobacillus rhamnosus, a specific bacterial strain, shares space with candida. Researchers found that the presence of this bacterium forced candida to make metabolic adjustments that directly compromised its ability to become pathogenic. In practical terms, the right bacterial neighbors can change candida's behavior at the chemistry level, not just compete for space. This adds a layer of specificity to the terrain conversation: it is not only about having bacteria present, but about what those bacteria are actively doing in the environment around candida.

Functional Medicine Connections:

Here is how these pieces fit together. Candida albicans has two forms: a quiet, single-cell form that lives harmlessly in roughly half of healthy adults, and an invasive, thread-like form that can compromise the gut lining and drive symptoms well beyond the digestive tract. What determines which form it takes is largely the environment around it, specifically what the surrounding bacterial community is producing and signaling.

When butyrate-producing bacteria are intact, they maintain an environment that keeps candida in its harmless state. When those populations are depleted, by antibiotic courses, chronic stress, blood sugar instability, or sustained dietary patterns, candida receives a different set of signals and responds accordingly. The Alonso-Roman study adds another dimension: specific bacterial strains don't just crowd candida out. They actively change its chemistry in ways that limit how harmful it can become.

This is why an antifungal course that produces clear short-term improvement doesn't prevent recurrence. It reduces the load, but it doesn't restore the suppressive capacity that keeps the load from returning. The terrain is the mechanism. When it isn't addressed, the pattern continues regardless of how effective the treatment was in the moment.

Practical Reflections & Takeaways:

If you've been through multiple rounds of antifungal treatment and found that symptoms improved and then returned, it may be worth asking: what changed in my gut environment before this started, and has that ever been directly addressed?

And if standard testing has come back unremarkable despite ongoing symptoms, it may be worth considering whether the bacterial ecosystem and its functional capacity have actually been evaluated, or whether that part of the picture has never been part of the conversation.

References:

- Marsaux, B., d'Hoker, W., Moens, F., Van Elst, D., Minnebo, Y., Marzorati, M., & Van de Wiele, T. (2025). Candida albicans colonization in the human colon correlates with a reduction in acetate- and butyrate-producing bacteria, as simulated using the M-SHIME® model. npj Biofilms and Microbiomes, 11, 176. https://doi.org/10.1038/s41522-025-00803-w
- Bays, D. J., & Savage, H. P. (2025). Candida albicans gastrointestinal colonization resistance: a host-microbiome balancing act. Infection and Immunity, 93(9), e0061024. PMID: 40788152.
- Alonso-Roman, R., Last, A., Mirhakkak, M. H., Sprague, J. L., Möller, L., Großmann, P., Graf, K., Gratz, R., Mogavero, S., Vylkova, S., Panagiotou, G., Schäuble, S., Hube, B., & Gresnigt, M. S. (2022). Lactobacillus rhamnosus colonisation antagonizes Candida albicans by forcing metabolic adaptations that compromise pathogenicity. Nature Communications, 13, 3192. PMID: 35680868.